precise-2-logo

GISSI Trial: EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION GRUPPO ITALIANO PER LO STUDIO DELLA STREPTOCHINASI NELL’INFARTO MIOCARDICO (GISSI)*

Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). [No authors listed] Abstract In an unblinded trial of intravenous streptokinase (SK) in early acute myocardial infarction, 11 806 patients in one hundred and seventy-six coronary care units were enrolled over 17 months. Patients admitted within 12 h after the onset of symptoms and with no contraindications to SK were randomised to receive SK in addition to usual treatment and complete data were obtained in 11 712. At 21 days overall hospital mortality was 10.7% in SK recipients versus 13% in controls, an 18% reduction (p = 0.0002, relative risk 0.81). The extent of the beneficial effect appears to be a function of time from onset of pain to SK infusion (relative risks 0.74, 0.80, 0.87, and 1.19 for the 0-3, 3-6, 6-9, and 9-12 h subgroups). SK seems to be a safe drug for routine administration in acute myocardial infarction. PMID: 2868337 [PubMed - indexed for MEDLINE]

Trial
Journal Ref. Lancet 1986 Feb 22;1(8478):397-402.
Intervention Drug - Intravenous thrombolytic treatment in acute myocardial infarction
Number of sites 176
Countries involved 1
Sample size 11806
Type of statistical analyses
Risk of bias Overall: Low Risk details
Duration of trial 21 days for this outcome; 12 months for long term follow up
Primary outcome 21 day mortality
Effect Measures
Events Intervention Total Events Control Total Risk Diff.
0 0
Show Score Ranges

Scores:

(shows median if more than one score was entered)

Elig. Recr. Setting Org. Int. Flex. Del. Flex. Adherence Follow-Up Prim. Out. Prim. An.
5 5 5 5 5 5 5 5 5